Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...

President Trump’s administration has made the decision not to cover highly-popular obesity treatments under the 2026 Medicare Advantage and Part D policies. One day after the Senate confirmed Dr ...

High-demand obesity treatments will not be covered under the federal government’s Medicare program, it was announced Friday. The Centers for Medicare and Medicaid Services said late Friday that ...

Improving access and affordability could be transformative for public health, given that about 88% of Americans are ...

Medicare coverage for anti-obesity drugs was not finalized, affecting drugs like Wegovy and Zepbound. Covering weight loss drugs may cost $35 billion from 2026–2034, with estimated savings under ...

Pennsylvania Governor Josh Shapiro's office has said it is looking to change eligibility for weight loss drugs as part of its ...

Insulin changed the way we treat and manage diabetes. Chemotherapy has precipitously reduced the mortality rate of certain ...

The Wegovy maker says the telehealth company didn't stop selling compounded versions of the blockbuster drug after Novo resolved its shortage.

The Biden administration proposal on obesity drugs. In November 2024, The Biden administration proposed a rule that would allow both Medicare and Medicaid to cover weight loss drugs beginning in ...